Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RALAM roll-over simplification study of once-daily lamivudine plus raltegravir
2017-000986-60Phase 3Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lamivudine and raltegravir in Human immunodeficiency virus infection type 1, sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Therapeutic failure at week 48. Started Aug 2017; status: terminated.
02
Drugs
lamivudineraltegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2017-000986-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000986-60.